Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 228-235 , May 2007

The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer

  • Mark L. Gonzalgo, M.D., Ph.D.

      Affiliations

    • Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    • ,
  • Ram H. Datar, Ph.D.

      Affiliations

    • Department of Pathology, USC–Keck School of Medicine, Los Angeles, CA 90033, USA
    • ,
  • Mark P. Schoenberg, M.D.

      Affiliations

    • Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    • ,
  • Richard J. Cote, M.D.

      Affiliations

    • Departments of Pathology and Urology, USC/Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-323-442-1156; fax: +1-323-442-1154.

Received 6 February 2006 ,Revised 20 June 2006 ,Accepted 14 July 2006.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006 (CA Cancer). J Clin. 2006;56:106–130
  2. Skinner DG, Lieskovsky GL. Management of invasive and high-grade bladder cancer. In:  Skinner DG,  Lieskovsky GL editor. Diagnosis and management of genitourinary cancer. Philadelphia,(PA): Saunders; 1988;p. 295–312
  3. Stonehill WH, Dmochowski RR, Patterson AL, et al. Risk factors for bladder tumors in spinal cord injury patients. J Urol. 1996;55:1248–1250
  4. Spruck CH, Ohnseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional carcinoma of the bladder. Cancer Res. 1994;54:784–788
  5. Cairns P, Shaw ME, Knowles MA. Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. Cancer Res. 1993;53:1230–1232
  6. Simoneau AR, Spruck CH, Gonzalez-Zulueta M. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res. 1996;56:5039–5043
  7. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–428
  8. Gonzalgo ML, Jones PA. Mutagenic and epigenetic effects of DNA methylation. Mutat Res. 1997;386:107–118
  9. Jones PA, Gonzalgo ML. Altered DNA methylation and genome instability: A new pathway to cancer?. Proc Natl Acad Sci U S A. 1997;94:2103–2105
  10. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell. 1992;69:915–926
  11. Coulondre C, Miller JH, Farabaugh PJ, et al. Molecular basis of base substitution hotspots in Escherichia coli. Nature. 1978;274:775–780
  12. Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease. Hum Genet. 1988;78:151–155
  13. Sved J, Bird A. The expected equilibrium of the CpG dinucleotide in vertebrate genomes under a mutation model. Proc Natl Acad Sci U S A. 1990;87:4692–4696
  14. Magewu AN, Jones PA. Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer. Mol Cell Biol. 1994;14:4225–4232
  15. Smith ND, Rubenstein JN, Eggener SE, et al. The p53 tumor suppressor gene and nuclear protein: Basic science review and relevance in the management of bladder cancer. J Urol. 2003;169:1219–1228
  16. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855–4878
  17. Rideout WM, Coetzee GA, Olumi AF, et al. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science. 1990;249:1288–1290
  18. Tornaletti S, Pfeifer GP. Complete and tissue-independent methylation of CpG sites in the p53 gene: Implications for mutations in human cancers. Oncogene. 1995;10:1493–1499
  19. Markl ID, Jones PA. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res. 1998;58:5348–5353
  20. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331:1259–1264
  21. Jones PA, Gonzalgo ML, Tsutsumi M, et al. DNA methylation in bladder cancer. Eur Urol. 1998;33:7–8
  22. Bird AP. CpG-rich islands and the function of DNA methylation. Nature. 1986;321:209–213
  23. Cedar H. DNA methylation and gene activity. Cell. 1988;53:3–4
  24. Bird AP, Wolffe AP. Methylation-induced repression–belts, braces, and chromatin. Cell. 1999;99:451–454
  25. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704–707
  26. Spruck CH, Gonzalez-Zulueta M, Shibata A, et al. p16 gene in uncultured tumors. Nature. 1994;370:183–184
  27. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525–4530
  28. Gonzalez-Zulueta M, Bender CM, Yang AS, et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995;55:4531–4535
  29. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001;61:8659–8663
  30. Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res. 2002;8:464–470
  31. Tada Y, Wada M, Kuroiwa K, et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res. 2000;6:4618–4627
  32. Habuchi T, Takahashi T, Kakinuma H, et al. Hypermethylation at 9q32–33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene. 2001;20:531–537
  33. Bornman DM, Mathew S, Alsruhe J, et al. Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am J Pathol. 2001;159:831–835
  34. Ribeiro-Filho LA, Franks J, Sasaki M, et al. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinog. 2002;34:187–198
  35. Pao MM, Tsutsumi M, Liang G, et al. The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet. 2001;10:903–910
  36. Salem CE, Markl ID, Bender CM, et al. PAX6 methylation and ectopic expression in human tumor cells. Int J Cancer. 2000;87:179–185
  37. Lee MG, Kim HY, Byun DS, et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res. 2001;61:6688–6692
  38. Dhawan D, Hamdy FC, Rehman I, et al. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Path. 2006;209:336–343
  39. Chang LL, Yeh WT, Yang SY, et al. Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J Urol. 2003;170:595–600
  40. Dominguez G, Carballido J, Silva J, et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res. 2002;8:980–985
  41. Muto S, Horie S, Takahashi S, et al. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res. 2000;60:4021–4025
  42. Gonzalgo ML, Hayashida T, Bender CM, et al. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res. 1998;58:1245–1252
  43. Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995;55:5195–5199
  44. Horikawa Y, Sugano K, Shigyo M, et al. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ. J Urol. 2003;169:1541–1545
  45. Ahuja N, Issa JP. Aging, methylation and cancer. Histol Histopathol. 2000;15:835–842
  46. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res. 2002;8:514–519
  47. Thievessen I, Seifert HH, Swiatkowski S, et al. E-cadherin involved in inactivation of WNT/beta-catenin signalling in urothelial carcinoma and normal urothelial cells. Br J Cancer. 2003;88:1932–1938
  48. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25:315–319
  49. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res. 2001;61:3105–3109
  50. Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001;10:687–692
  51. Velicescu M, Weisenberger DJ, Gonzales FA, et al. Cell division is required for de novo methylation of CpG islands in bladder cancer cells. Cancer Res. 2002;62:2378–2384
  52. Jurgens B, Schmitz-Drager BJ, Schulz WA. Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma. Cancer Res. 1996;56:5698–5703
  53. Kimura F, Seifert HH, Florl AR, et al. Decrease of DNA methyltransferase 1 expression relative to cell proliferation in transitional cell carcinoma. Int J Cancer. 2003;104:568–578
  54. Gonzalgo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res. 1997;25:2529–2531
  55. Liang G, Salem CE, Yu MC, et al. DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics. 1998;53:260–268
  56. Markl ID, Cheng J, Liang G, et al. Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over time. Cancer Res. 2001;61:5875–5884
  57. Liang G, Gonzales FA, Jones PA, et al. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res. 2002;62:961–966
  58. Xiong Z, Laird PW. COBRA: A sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997;25:2532–2534
  59. Trinh BN, Long TI, Laird PW. DNA methylation analysis by MethyLight technology. Methods. 2001;25:456–462
  60. Adorjan P, Distler J, Lipscher E, et al. Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Res. 2002;30:e21
  61. Goessl C, Muller M, Straub B, et al. DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol. 2002;41:668–676
  62. Valenzuela MT, Galisteo R, Zuluaga A, et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur Urol. 2002;42:622–628
  63. Tada Y, Wada M, Taguchi K, et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res. 2002;62:4048–4053
  64. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 1998;58:95–101
  65. Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst. 2003;95:399–409
  66. Yang SA, Doshi KD, Choi S-W, et al. DNA methylation changes after 5-Aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006;66:5495–5503

☆ The Molecular and Cellular Pathways of Bladder Cancer Progression Grant (No. NCI CA 70903), the Cancer Center Core Grant (NCI CA 14089), and the Bladder Cancer Program Project Grant (No. PO1 CA 86871) provided research support for R.H.D. and R.J.C.

PII: S1078-1439(06)00242-0

doi: 10.1016/j.urolonc.2006.07.020

Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 228-235 , May 2007

Article Tools

* Image Usage & Resolution